Pharmacotherapy Pipeline

The obesity pharmacotherapy pipeline is the most active in medicine with multiple late-stage candidates. The session covers triple agonists (retatrutide TRIUMPH-4, mazdutide phase 3 in China and globally), oral GLP-1 (orforglipron Novo Nordisk, danuglipron Pfizer programme), once-monthly long-acting MariTide (Amgen), amycretin (Novo dual GLP-1/amylin), and combination strategies with bone- and muscle-protective agents. Discussion addresses pipeline drug-class comparisons mechanistically, the head-to-head trials emerging (SURPASS-CVOT), GIP-only agonism and antagonism debate, GLP-1/glucagon dual agonists (survodutide), and the regulatory landscape for the next-generation obesity drugs.